Navigation Links
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Date:12/3/2008

CARLSBAD, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that OncoGenex Pharmaceuticals, Inc. provided positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm") compared to docetaxel and prednisone alone ("the control arm") for first-line treatment of metastatic castrate resistant prostate cancer. The current 10.6 month median overall survival advantage observed in the OGX-011 arm represents an increase over the median survival observed in the control arm. OGX-011 was jointly discovered by Isis and the initial development was conducted by Isis and OncoGenex. OGX-011 is now being developed by OncoGenex.

"The progress our partners are making with antisense drugs discovered using Isis' antisense technology demonstrates the value of our technology to create drugs that are first-in-class and may provide new treatment options in a broad range of diseases, including cancer," said Stanley Crooke, Chairman and Chief Executive Officer of Isis. "We are encouraged by the latest results from OGX-011 and look forward to OncoGenex announcing the full results of the study next year."

According to OncoGenex' announcement, the Phase 2 randomized study in 82 patients with metastatic or locally recurring prostate cancer refractory to hormone therapy showed a median survival of 27.5 months for the patients in the OGX-011 arm and 16.9 months for patients in the control arm. Results currently indicate that patients in the OGX-011 arm have a death rate approximately 40% lower than patients in the control arm. The current results were based on study data with a median follow-up of approximately 30 months for both arms. OncoGenex indicates that additional survival updates will be needed before mature me
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Qualcomm Incorporated (NASDAQ: QCOM ) ... Inc., is collaborating with Davita Healthcare Partners ... powered by Qualcomm Life,s 2net™ Device Connectivity Platform ... care, informed interventions and better management of at-risk ... annual Connect 2015 ecosystem conference taking ...
(Date:8/31/2015)... 31, 2015 Premune ... an exclusive licensing agreement for Redonyl ® Ultra. ... million USD veterinary dermatology market, is a nutritional supplement ... healthy skin in dogs and cats. Redonyl ® ... , and has been received positively in the country ...
(Date:8/31/2015)... 31, 2015   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade cell and ... freeze media and a related cloud ... smart shippers ("BioLife" or the "Company"), ... advanced biopharmaceutical company focused on developing and commercializing ...
Breaking Medicine Technology:Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5
... , OKLAHOMA CITY , July 12 For the ... to receive its prestigious R&D 100 Award.  Orthocare Innovations received this ... reporting the function of persons who have experienced lower limb loss, injury ... (Logo:   ...
... 12 Holon, the new standard for healthcare interoperability, ... , , ... the Holon Process Adaptive Interoperability Framework, Holon introduces a cost-effective ... solution by automating the collection and distribution of pharmacy information ...
Cached Medicine Technology:Orthocare Innovations Receives Prestigious R&D 100 Award for Novel Web-Based Rehabilitation Outcomes Assessment System 2Holon: The Process Adaptive Interoperability Framework 2
(Date:8/31/2015)... ... 2015 , ... “My mother and husband use oxygen therapy and the tubing ... there could be a comfortable way to prevent the irritation, so I invented this.” ... a more secure way to anchor the cannula tubing used in oxygen therapy and ...
(Date:8/31/2015)... ... August 31, 2015 , ... For 12 years, since ... acknowledged September 26th as Mesothelioma Awareness Day . On this day, and in ... several ways of becoming involved and helping the cause. , “One of the ways ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... communities in and around Grand Prairie, is teaming up with the Tarrant County ... the area. , Meals on Wheels is the oldest and largest national organization ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... nonprofit authority on the use of health IT to create efficiencies in healthcare ... WEDI-Con 2015 . Taking place at the Hyatt Regency Reston in Reston, ...
(Date:8/31/2015)... ... August 31, 2015 , ... Juvent Sports ( http://www.juvent.com ) ... major sports figures who are finding joint pain relief after using their revolutionary Micro-Impact ... tennis player in the world said, “For the first time in over 20 years ...
Breaking Medicine News(10 mins):Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 2Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 3Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 2Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 3Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3
... first U.S. clinical trial using genetic screening to ... therapies supports the use of those drugs as ... failed. While the study led by Massachusetts General ... (Iressa) treatment considerably improved the outcomes for non-small-cell-lung-cancer ...
... at the University of Illinois report this week that a ... can disrupt a key component of the inflammatory response in ... and diseases such as Alzheimers and multiple sclerosis. , ... Academy of Sciences. , Inflammation can be a blessing or ...
... the ... chance to change people,s lives, OTTAWA, May 20 ... for new ways to make the most of their,time, especially ... independent marketing opportunities provided by,Melaleuca, The Wellness Company(R)., One ...
... Anthem,s Care Comparison Tool Gives Members the Most Complete Picture ... Costs Associated with Medical ... Cross and,Blue Shield (Anthem) announced today the expansion of its ... access,to Anthem Care Comparison, an online tool that provides total ...
... WASHINGTON, May 20 Wednesday, May 21, 2008,Easter Seals ... Senator Mary Landrieu and Capital One for,their efforts on ... Advocacy Awards Benefit will be held at the JW ... pm and dinner at 7:00,pm. Gordon Peterson of WJLA ...
... May 20 Despite the clear benefits of,lipid-modifying ... in a new supplement to The Journal of ... aggressive,lipid lowering" reviews the evidence from recent trials ... and the use of,statins to improve outcomes in ...
Cached Medicine News:Health News:Determining genetic signature of lung tumors can help guide treatment 2Health News:Determining genetic signature of lung tumors can help guide treatment 3Health News:Plant flavonoid found to reduce inflammatory response in the brain 2Health News:Plant flavonoid found to reduce inflammatory response in the brain 3Health News:Lucrative Sales Opportunities Abound With Melaleuca, The Wellness Company(R) 2Health News:Anthem Blue Cross and Blue Shield Introduces Transparency Initiative in Maine 2Health News:Anthem Blue Cross and Blue Shield Introduces Transparency Initiative in Maine 3Health News:Reductions in CV Morbidity and Mortality are Achievable! 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: